trial · primary record
Pembrolizumab
Renal Cell Carcinoma
| Phase | Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 160 |
| Primary completion | 2025-10-21 |
| Primary endpoint | Objective Response Rate (ORR) |
| Registry ID | NCT04704219 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:54.186Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04704219
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Pembrolizumab · approval
- Pembrolizumab · compound